Home › Funds › Vestal Point Capital, LP › RCUS
Vestal Point Capital, LP position in RCUS
ARCUS BIOSCIENCES INC · Health Care
Vestal Point Capital, LP reported holding 1,300,000 shares of RCUS (ARCUS BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$33.6M, representing 0.87% of its reported portfolio and ranking #21 among its reported holdings. Vestal Point Capital, LP has disclosed RCUS holdings in 2 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's RCUS position evolved
Vestal Point Capital, LP first disclosed a stake in RCUS in Q3 2025 at 250,000 shares (US$3.4M). The position peaked in Q3 2026 at 1,300,000 shares, worth US$33.6M. Across 2 filings, Vestal Point Capital, LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,300,000 shares valued at US$33.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 250.00K | $3.40M | New |
| Q3 2026 | 1.30M | $33.58M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RCUS and 13F data
RCUS (ARCUS BIOSCIENCES INC) is a Health Care company. 41 other funds we track also report a position in RCUS — the largest reported positions include GILEAD SCIENCES, INC. (US$811.7M), Siren, L.L.C. (US$62.5M), SAMLYN CAPITAL, LLC (US$36.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RCUS
- GILEAD SCIENCES, INC. 31.42M sh · $811.70M · Q3 2026
- Siren, L.L.C. 2.42M sh · $62.52M · Q3 2026
- SAMLYN CAPITAL, LLC 1.39M sh · $36.03M · Q3 2026
- Soleus Capital Management, L.P. 862.00K sh · $22.27M · Q3 2026
- BAKER BROS. ADVISORS LP 844.82K sh · $21.82M · Q3 2026
- Ikarian Capital, LLC 734.56K sh · $18.97M · Q3 2026
- Parkman Healthcare Partners LLC 675.52K sh · $17.45M · Q3 2026
- Sofinnova Investments, Inc. 626.18K sh · $16.17M · Q3 2026
- First Turn Management, LLC 577.69K sh · $14.92M · Q3 2026
- Logos Global Management LP 500.00K sh · $12.91M · Q3 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held RCUS?
Vestal Point Capital, LP has disclosed RCUS holdings in 2 of the last 5 reported quarters, going back to Q3 2025.
What is Vestal Point Capital, LP's current position in RCUS?
As of Q3 2026, Vestal Point Capital, LP holds 1.30M shares of RCUS (ARCUS BIOSCIENCES INC), valued at $33.58M, representing 0.87% of its reported portfolio and ranking #21.
Has Vestal Point Capital, LP been buying or selling RCUS?
In the latest 13F filing (Q3 2026), Vestal Point Capital, LP newly opened its position in RCUS. The position peaked in Q3 2026 at 1.30M shares.
Which other funds hold RCUS?
Other major institutional holders of RCUS include GILEAD SCIENCES, INC., Siren, L.L.C., SAMLYN CAPITAL, LLC, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.